Merck KGaA eyes up to 700 million eur Mavenclad sales in EU

Share this post

FRANKFURT (Reuters) – Germany’s Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply